Skip to main content Deutsch



  1. Kyrle PA, et al. Inhibition of prostacyclin and thromboxane A2 generation by low dose aspirin at the site of plug formation in man in vivo. Circulation. 1987; 75: 1025-1029.
  2. Greengard J, Eichinger S, et al. Variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg Gl mutation in the gene for factor V. N Engl J Med 331:1559-1562, 1994
  3. Eichinger S, et al. The risk of recurrent venous thromboembolism in patients without and with factor V Leiden. Thromb Haemost 1997; 77: 624-628   
  4. Furlan M, ..., Kyrle PA, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998; 339: 1578-1584
  5. Kyrle PA, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343: 457-462.
  6. Eichinger S et al. D-Dimer levels and risk of recurrent venous thromboembolism. JAMA 2003; 290:1071-74.
  7. Kyrle PA et al. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004; 350: 2558-63
  8. Hron G, …, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 2006; 296: 397-402.
  9. Eichinger S et al. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: The Vienna prediction model. Circulation 2010; 121:1630-6. (editor’s pick)
  10. Becattini C, …, Eichinger S, et al. for the WARFASA Investigators. Aspirin for prevention of recurrence of venous thromboembolism. N Engl J Med 366:1959-67, 2012
  11. Kyrle PA et al. The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study. J Thromb Haemost. 2016; 14:2402-09.
  12. Traby L, … Kyrle PA. Effects of P2Y12 receptor inhibition with or without aspirin on hemostatic system activation: a randomized trial in healthy subjects. J Thromb Haemost. 2016; 14:273-81
  13. Eichinger S et al.  Natural antibodies to oxidation-specific epitopes: innate immune response and venous thromboembolic disease. J Thromb Haemost. 2018;16:31-35
  14. Greinacher A, …., Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med. 2021;384(22):2092-2101.
  15. Eichinger S. Reversing vitamin K antagonists: making the old new again. Hematology Am Soc Hematol Educ Program. 2016:605-611, 2016 (invited)